ESMO Advanced Course on Metastatic EGFR Mutant NSCLC 2016

Oncology Meeting Resources

28 Oct - 29 Oct, Seoul, Korea, Republic of

ESMO Advanced Course Metastatic NSCLC Square

The ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC 2016 was designed for understanding the biology and role of EGFR and TKI’s (1st, 2nd, 3rd generation) in the management of NSCLC; understanding the development of resistance to TKI’s and the available treatment options; understanding the role of T790M in the development of resistance; understanding the utility of different diagnostic methods in identifying the resistance mechanism and understanding the importance of the multidisciplinary team and particularly the pathologist and radiologists in optimising diagnosis and selection of the most appropriate treatment options

Presentations of the ESMO Advanced Course on Metastatic EGFR-Mutant NSCLC 2016 are available according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links

Presenter Presentation title Session title
R. A. Stahel, CH Targeting Oncogenetic Drivers in NSCLC Session 1 - The already long journey of EGFR TKI
Myung-Ju Ahn Treatment of EGFR resistant patients with T790M as resistance mechanisms Session 1 – The already long journey of EGFR TKI
Byoung Chul Cho Mechanisms of 1st generation resistance Session 1 – The already long journey of EGFR TKI
Sanjay Popat Contribution of 2nd generation TKI in 1st or 2nd line Session 1 – The already long journey of EGFR TKI
Tony Mok 1st line treatment of EGFR m+: benefit from 1st generation TKI vs. Chemo Session 1 – The already long journey of EGFR TKI
Rolf Stahel Targeting oncogenetic drivers in NSCLC Session 1 – The already long journey of EGFR TKI
T. Mok, HK First line Treatment of EGFR m+: Benefit from First Generation TKI vs. Chemo Session 1 - The already long journey of EGFR TKI
S. Popat, UK Contribution of 2nd Generation TKI in 1st or 2nd Line Session 1 - The already long journey of EGFR TKI
B. C. Cho, KR Mechanisms of 1st Generation Resistance Session 1 - The already long journey of EGFR TKI
M. Ahn, KR Treatment of EGFR Resistant Patients with T790M as Resistance Mechanisms Session 1 - The already long journey of EGFR TKI
E. Thunnissen, NL Biopsy - Key to the Diagnostics Initially and at Progression Session 2 - Molecular diagnostics of EGFR and T790Mm - Challenges and solutions
Rolf Stahel ESMO Guidelines in advanced NSCLC in 2016 Session 2 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions
Yuichiro Ohe Progression after third generation TKI – what next? Session 2 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions
Ross Soo Strategy to improve outcome in EGFR mutant NSCLC Session 2 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions
Ji-Youn Han Associations between diagnostics and clinical outcomes (incl. patient handling algorithm) Session 2 – Molecular diagnostics of EGFR and T790Mm – Challenges and solutions